Pfizer’s zeroes in on Medivation with its offer of a little more than $80 per share. According to sources familiar with the matter at hand, Pfizer Inc. is said to be in advanced talks with Medivation Inc. so as to… Read More ›
Top, Pfizer, Medivation, cancer treatment, breast cancer drug, prostrate cancer drug, Xtandi, Talazoparib, merger and acquisition, M&A,
manageria.biz 